Business
Precigen Reports First Quarter 2022 Financial Results and Business Updates
– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly
About this update from Precigen, Inc.
[{"type":"text","content":"– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment options –\n – Phase 1b expansion arm initiated for PRGN-3006 UltraCAR-T® at Dose Level 3 with lymphodepletion –\n– Dosing initiated in patients at Dose Level 3 via intravenous infusion with lymphodepletion in the PRGN-3005 UltraCAR-T® Phase 1 study –\n– Phase 2 study initiated for PRGN-2012 AdenoVerse™ Immunotherapy as an adjuvant treatment in patients with recurrent respiratory papillomatosis –\n– Cash, cash equivalents, short-term and long-term investments totaled $142.1 million as of March 31, 2022 –\n– Company to host a pipeline update call in the coming months –\nGERMANTOWN, Md., May 9, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2022 financial results and business updates.\n\n \n \n \n \n \n \n\n \n\"Precigen's portfolio has been prioritized based on the positive preliminary data we have seen for key programs and we are exploring potential rapid paths to licensure with the FDA for programs with compelling data in diseases that have a high unmet medical need. The FDA Fast Track designation recently received for PRGN-3006 UltraCAR-T will help facilitate development and expedite the review process and is an important milestone for patients with relapsed or refractory acute myeloid leukemia,\" said Helen Sabzevari, PhD, President and CEO of Precigen. \"As a result of these advancements, we look forward to hosting a call to provide pipeline updates in the coming months.\"\n\"We remain focused on enhancing our financial position, expanding our financial flexibility, and extending our cash runway to help Precigen achieve our near-term objectives,\" said Harry Thomasian Jr., CFO of Precigen. \"As the year progresses, we intend to expound on these initiatives.\"\nKey Business Highlights\nPRGN-3006 UltraCAR-T® in Acute Myeloid Leukemia (AML) In April 2022, Precigen announced that the US Food and Drug Administration (FDA) granted Fast Track designation for PRGN-3006 UltraCAR-T in patients with relapsed or refractory (r/r) AML. Fast Track designation facilitates develop...